This study is testing pembrolizumab, a type of immunotherapy, in people with certain ultra-rare sarcomas. Pembrolizumab works by blocking a protein called PD-1, which helps release the "brakes" on your immune system so it can better fight cancer cells. The main goal is to see how many participants respond to the treatment after 12 weeks and if it causes few or mild side effects. Researchers will also study how your immune system reacts to the treatment. You may be able to join if you are an adult with a confirmed diagnosis of pleomorphic liposarcoma, PEComa, epithelioid sarcoma, CIC-rearranged sarcoma, or SEF/LGFMS. The study plans to enroll 32 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 32 participants.

What's involved

Participants will receive pembrolizumab as an intravenous (IV) infusion every 6 weeks, for up to 8 doses.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures response rate at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.